Piriformis Syndrome Market Share

Piriformis Syndrome Market Overview

The Piriformis Syndrome Market is expected to reach USD 245.44 Million by 2030 at 6.10% CAGR during the forecast period 2022-2030.

Piriformis syndrome is a rare neuromuscular condition that is caused when the piriformis muscle compresses the sciatic nerve. The piriformis muscle is a flat, band-like muscle located in the buttock near the upper region of the hip joint. Piriformis syndrome mostly occurs in adults and can affect individuals from any field and activity levels. The common causes of piriformis syndrome are considered to be trauma, spasms, and overuse injury. Additionally, according to the National Center for Biotechnology Information (NCBI), the piriformis syndrome is more prevalent in patients with pain in the lower back.

The piriformis syndrome market is majorly driven by the increase in the occurrences of piriformis syndrome, increasing screening, rising safety and success of drug treatments, and the growing geriatric population. The market restraints include the complications of surgeries, lack of awareness about the syndrome, and others. Furthermore, challenges in the diagnosis of the syndrome among the patient pool may hamper the growth of the market.

Research Methodology

Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, treatment assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.

• Primary Research

Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.

• Secondary Research

Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the piriformis syndrome market. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and treatment perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases and many others.

Key Players in the Piriformis Syndrome Market

• Bayer AG


• Novartis AG


• AstraZeneca


• Endo Pharmaceuticals


• Teva Pharmaceuticals


• Omron Healthcare


• Sanofi S.A.


• DePuy Synthes Companies


• Miracle Stretch, LLC


• Flex Pharma, Inc.


• Nidd valley medical


• SEIRIN Corporation


• Others

Piriformis Syndrome Market Segmentation

The piriformis syndrome market is segmented on the basis of cause, diagnostic test, treatment, distribution channel, and end-user.

On the basis of cause, the market is classified as trauma, spasms, overuse injury, and others.

The piriformis syndrome market on the basis of diagnostic tests is segmented as Magnetic Resonance Imaging (MRI), X-ray, Computed Tomography (CT), neurophysiologic testing, Electromyography (EMG), Beatty Test, FAIR (Flexion, adduction, and Internal Rotation) test, and others.

On the basis of treatment, the market is segmented into medication, physical therapy, acupuncture, prolotherapy, Osteopathic Manipulative Treatment (OMT), surgery, and others. The medication is further segmented into Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), piriformis muscle injection, and others. NSAIDs are further segmented into naproxen, ibuprofen, and others. Further, the piriformis muscle injection is segmented into Botox injection, steroid injections, and others.

The piriformis syndrome market, by distribution channel, is segmented into E-commerce, retail pharmacies, and others.

On the basis of end-user, the market is segmented as hospitals and clinics, diagnostic centers, and others.

Geographically, the piriformis syndrome market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American market is further segmented into North America and South America. North America is further classified as the US and Canada.

The European piriformis syndrome market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The piriformis syndrome market in Asia-Pacific is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia-Pacific.

The Middle Eastern and African market is segmented into the Middle East and Africa.

Piriformis Syndrome Market Regional Analysis

The piriformis syndrome market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The North American region is anticipated to dominate the market due to the existing well-established healthcare system, increasing healthcare expenditure, growing awareness about the syndrome, and rising geriatric population. 

For instance, according to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the US was reported to be 3.2 USD trillion. Additionally, the high concentration of major hospitals in developed countries of this region coupled with good reimbursement rates is fueling the growth of the market. Moreover, a large number of prominent companies in the US is likely to contribute to the faster development of the piriformis syndrome market in this region.

Europe is expected to hold the second largest market share in the market. It is expected that the government support towards research and development expenditure and increasing secondary lifestyle are likely to drive the market.  Moreover, the market growth in Europe is led by countries such as Germany and France.

The piriformis syndrome market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The market growth in this region is driven by the rising healthcare expenditure and growing penetration of the healthcare industry in this region.

The Middle East & Africa holds the lowest share of the piriformis syndrome market. The African region is anticipated to witness a poor market growth owing to poor economic and political conditions and poor healthcare infrastructure.

The Market of Piriformis syndrome, by Cause

• Trauma


• Spasms


• Overuse injury


• Others

The Market of Piriformis syndrome, by Diagnostic Test

• Magnetic Resonance Imaging (MRI)


• Computed Tomography (CT)


• X-rays


• Neurophysiologic Testing


• Electromyography (EMG)


• Beatty Test


• FAIR (Flexion, adduction, and Internal Rotation) Test


• Others

The Market of Piriformis syndrome, by Treatment

• Medication


• NSAIDS


• Naproxen


• Ibuprofen


• Others


• Piriformis Muscle Injection


• Botox Injection


• Steroid Injection


• Others


• Physical Therapy


• Acupuncture


• Prolotherapy


• Osteopathic Manipulative Treatment (OMT)


• Surgery


• Others

The Market of Piriformis syndrome, by Distribution Channel

• E-Commerce


• Retail Pharmacies


• Others

The Market of Piriformis syndrome, by End-User

• Hospitals & Clinics


• Diagnostic Centers


• Others

The Market of Piriformis syndrome, by Region

• Americas


• North America


• US


• Canada


• South America


• Europe


• Western Europe


• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe


• Eastern Europe


• Asia-Pacific


• Japan


• China


• India


• Australia


• Republic of Korea


• Rest of Asia-Pacific


• The Middle East & Africa


• Middle East


• Africa

Intended Audience

• Pharmaceutical Companies


• Research and Development (R&D) Companies


• Diagnostic Laboratories


• Government Research Institute


• Academic Institutes and Universities